Global Ischemic Heart Disease (IHD) Drugs Market to grow at a CAGR of 3.61% during 2019

MarketResearchReports.Biz has announced addition of new report “Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019” to its database.

About IHD

IHD is an abnormal condition of the human body marked by narrowing or blocking of the arteries that supply blood to the heart. It results from the buildup of plaque in the arteries. The condition often arises during excitement and exertion when heart requires more blood supply. This leads to recurrent chest pain and discomfort due to lack of sufficient blood supply, a condition known as angina pectoris.

Prolonged blockage of the arteries due to lack of blood supply may result in death of tissues in the heart, leading to myocardial infarction. The symptoms develop slowly, and in most cases the condition is asymptomatic until it reaches the last stages. The common indications include chest pain and shortness of breath. Treatment options are available depending on the condition of the patient. A range of medications of different classes, such as statins, antiplatelet drugs, nitrates, beta-blockers, etc. can be chosen from. Surgical procedures, such as angioplasty and coronary artery bypass graft, are also opted in serious scenarios.

Technavio analysts forecast the global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. IHD includes:

Angina pectoris

Myocardial infarction.

The Technavio report, namely Global IHD Drugs Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. We covers the Americas, APAC and EMEA markets. We also discuss the key vendors operating in this market.

Key Regions

Americas

EMEA

APAC

Key Vendors

AstraZeneca

Bayer

Eli Lilly

Novartis

Pfizer

Sanofi

Download Sample Copy of report at http://www.marketresearchreports.biz/sample/sample/354315

Other Prominent Vendors

Actelion

Amgen

Baxter

Boehringer Ingelheim

Bristol-Myers Squibb

Daiichi-Sankyo

Eisai

F.Hoffmann-La Roche

Gilead Sciences

GlaxoSmithKline

Human Stem Cells Institute

Janssen Pharmaceuticals

Juventas Therapeutics

Lacer

Merck

Nuo Therapeutics

Ono Pharmaceutical

Pharmahungary Group

Resverlogix

Takeda Pharmaceutical Company

Taxus Cardium

The Medicines Company

United Therapeutics

Market Driver

Rise in Number of Patients

For a full and detailed list, view our report

Market Challenge

Delayed Diagnosis

For a full and detailed list, view our report

Market Trend

Increase in Health Awareness

For a full and detailed list, view our report

Key Questions Answered in this Report

What will the market size be in 2019 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

About Us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Browse Latest Industry Press Release http://www.marketresearchreports.biz/pressreleases

Contact Us

State Tower

90 State Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz